A Phase I/II Trial to Evaluate Oral HP568 Tablets in Patients with ER+/HER2 Advanced Breast Cancer

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

204

Participants

Timeline

Start Date

January 7, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

November 27, 2026

Conditions

Breast Cancer

Interventions

DRUG

HP568

In the I/II stage: HP568 administered QD or BID for 28 day cycles.

DRUG

HP568 in combination with palbociclib

In the III stage: Daily oral dosages of HP568 for 28 days in combination with palbociclib for 21 days.